MedTrace Logo

Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma

NCT00846456 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-10-20

No results posted yet for this study

Summary

The study induces an immune response towards the stem-cell like part of glioblastomas in combination with standard therapy. The aim is to define and characterize the feasibility, potential adverse effects of such therapy and measure time to progression and survival.

Conditions

Interventions

BIOLOGICAL

Dendritic cell vaccine with mRNA from tumor stem cells

Intradermal injection of transfected dendritic cells

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Steinar Aamdal, MD, PhD · Department of Clinical Cancer Research, Rikshospitalet

  • Iver A Langmoen, MD, PhD · Dept of Neurosurgery, Ulleval University Hospital

  • Gunnar Kvalheim, MD, PhD · Dept of cellular therapy, Rikshospitalet HF

  • Gustav Gaudernack, PhD · Inst. of Immunotherapy, Rikshospitalet HF

  • Knut Lote, MD, PhD · Dept. of oncology, Rikshospitalet HF

  • Jon Berg-Johnsen, MD, PhD · Dept. of Neurosurgery, Rikshospitalet HF

  • Carl Langberg, MD, PhD · Dept of oncology, Ulleval University Hospital

  • Marta Nyakas, MD · Dept. of Clinical Cancer Research, Rikshospitalet HF

  • Einar O Vik-Mo, MD · Dept of Neurosurgery, Ulleval University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-02-28
Completion
2013-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00846456 on ClinicalTrials.gov